Irhythm Technologies (NASDAQ: IRTC) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Irhythm Technologies to similar companies based on the strength of its analyst recommendations, profitability, earnings, dividends, institutional ownership, valuation and risk.
Risk & Volatility
Irhythm Technologies has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Irhythm Technologies’ rivals have a beta of 0.80, indicating that their average share price is 20% less volatile than the S&P 500.
98.6% of Irhythm Technologies shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 23.3% of Irhythm Technologies shares are owned by company insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Irhythm Technologies and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Irhythm Technologies Competitors||-62.26%||-47.35%||-18.28%|
This is a summary of current ratings and price targets for Irhythm Technologies and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Irhythm Technologies Competitors||491||1884||3747||116||2.56|
Irhythm Technologies currently has a consensus target price of $71.17, indicating a potential upside of 12.61%. As a group, “Surgical & medical instruments” companies have a potential upside of 7.84%. Given Irhythm Technologies’ stronger consensus rating and higher probable upside, research analysts clearly believe Irhythm Technologies is more favorable than its rivals.
Valuation & Earnings
This table compares Irhythm Technologies and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Irhythm Technologies||$98.51 million||-$29.42 million||-48.62|
|Irhythm Technologies Competitors||$1.54 billion||$111.80 million||-146.59|
Irhythm Technologies’ rivals have higher revenue and earnings than Irhythm Technologies. Irhythm Technologies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Irhythm Technologies beats its rivals on 9 of the 13 factors compared.
Irhythm Technologies Company Profile
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.